Larimar Therapeutics (LRMR) Competitors $3.88 +0.13 (+3.47%) Closing price 04:00 PM EasternExtended Trading$3.87 -0.01 (-0.26%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. IOVA, QURE, XERS, NUVB, TRVI, KALV, CRON, SION, OCS, and VIRShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Iovance Biotherapeutics (IOVA), uniQure (QURE), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), KalVista Pharmaceuticals (KALV), Cronos Group (CRON), Sionna Therapeutics (SION), Oculis (OCS), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Iovance Biotherapeutics uniQure Xeris Biopharma Nuvation Bio Trevi Therapeutics KalVista Pharmaceuticals Cronos Group Sionna Therapeutics Oculis Vir Biotechnology Larimar Therapeutics (NASDAQ:LRMR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability. Do analysts rate LRMR or IOVA? Larimar Therapeutics presently has a consensus target price of $18.50, indicating a potential upside of 376.80%. Iovance Biotherapeutics has a consensus target price of $12.22, indicating a potential upside of 290.49%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Iovance Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Iovance Biotherapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to LRMR or IOVA? In the previous week, Iovance Biotherapeutics had 17 more articles in the media than Larimar Therapeutics. MarketBeat recorded 18 mentions for Iovance Biotherapeutics and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.87 beat Iovance Biotherapeutics' score of 0.14 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Larimar Therapeutics Very Positive Iovance Biotherapeutics Neutral Is LRMR or IOVA more profitable? Larimar Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Iovance Biotherapeutics' return on equity of -49.71% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -52.48% -46.08% Iovance Biotherapeutics -176.49%-49.71%-39.18% Do insiders & institutionals believe in LRMR or IOVA? 91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, LRMR or IOVA? Larimar Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Which has better valuation and earnings, LRMR or IOVA? Larimar Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.49-2.60Iovance Biotherapeutics$212.68M4.91-$372.18M-$1.24-2.52 SummaryLarimar Therapeutics beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.44M$2.82B$5.74B$9.51BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-2.609.0428.1120.03Price / SalesN/A744.02461.37103.88Price / CashN/A166.2336.5559.01Price / Book1.445.168.655.90Net Income-$80.60M$30.99M$3.25B$258.66M7 Day Performance20.87%7.74%4.20%2.23%1 Month Performance19.38%16.18%10.82%12.76%1 Year Performance-58.81%-1.03%34.70%19.36% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics2.4684 of 5 stars$3.88+3.5%$18.50+376.8%-60.5%$248.44MN/A-2.6030Positive NewsIOVAIovance Biotherapeutics4.6236 of 5 stars$2.49+11.7%$12.22+390.9%-64.0%$831.49M$164.07M-2.01500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeQUREuniQure2.3882 of 5 stars$14.50-3.3%$37.82+160.8%+88.2%$821.09M$20.20M-3.30500XERSXeris Biopharma4.0471 of 5 stars$5.14+0.6%$6.25+21.6%+114.5%$803.79M$203.07M-17.13290News CoveragePositive NewsNUVBNuvation Bio1.8672 of 5 stars$2.36+2.4%$7.17+204.3%-30.1%$801.31M$7.87M-1.0060Gap UpTRVITrevi Therapeutics3.8764 of 5 stars$6.82-0.6%$20.88+206.1%+164.0%$799.92MN/A-15.1620Positive NewsKALVKalVista Pharmaceuticals4.1141 of 5 stars$15.56+1.1%$26.29+68.9%+7.8%$777.22MN/A-4.22100CRONCronos Group2.0405 of 5 stars$2.09+4.0%N/A-12.7%$775.22M$117.61M0.00450News CoverageSIONSionna TherapeuticsN/A$17.44+4.2%$38.50+120.8%N/A$769.45MN/A0.0035OCSOculis2.2535 of 5 stars$17.50flat$35.33+101.9%+51.0%$764.09MN/A-6.632VIRVir Biotechnology3.6999 of 5 stars$5.52+2.0%$30.25+448.0%-43.0%$763.09M$74.21M-1.31580 Related Companies and Tools Related Companies Iovance Biotherapeutics Alternatives uniQure Alternatives Xeris Biopharma Alternatives Nuvation Bio Alternatives Trevi Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Cronos Group Alternatives Sionna Therapeutics Alternatives Oculis Alternatives Vir Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
